@article{3089644,
    title = "The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia",
    author = "Panidis, D. and Georgopoulos, N.A. and Piouka, A. and Katsikis, I. and Saltamavros, A.D. and Decavalas, G. and Diamanti-Kandarakis, E.",
    journal = "Gynecological Endocrinology",
    year = "2011",
    volume = "27",
    number = "8",
    pages = "587-592",
    issn = "0951-3590, 1473-0766",
    doi = "10.3109/09513590.2010.507283",
    keywords = "androstenedione;  cyproterone acetate;  drospirenone;  ethinylestradiol;  follitropin;  glucose;  hydroxyprogesterone;  insulin;  luteinizing hormone;  metformin;  Muellerian inhibiting factor;  oral contraceptive agent;  prasterone sulfate;  prolactin;  sex hormone binding globulin;  testosterone, adult;  androstenedione blood level;  anovulation;  article;  body mass;  clinical article;  cohort analysis;  comparative study;  controlled study;  enzyme linked immunosorbent assay;  female;  follitropin blood level;  follow up;  glucose blood level;  human;  hyperandrogenism;  insulin blood level;  luteinizing hormone blood level;  menstrual cycle;  menstruation;  ovary polycystic disease;  priority journal;  prolactin blood level;  prospective study;  randomized controlled trial;  testosterone blood level;  treatment duration, Adolescent;  Adult;  Androgen Antagonists;  Androstenes;  Anti-Mullerian Hormone;  Blood Glucose;  Body Mass Index;  Cohort Studies;  Contraceptives, Oral, Combined;  Cyproterone Acetate;  Drug Combinations;  Ethinyl Estradiol;  Female;  Humans;  Hyperandrogenism;  Hypoglycemic Agents;  Insulin Resistance;  Metformin;  Polycystic Ovary Syndrome;  Practice Guidelines as Topic;  Young Adult",
    abstract = "Objective.?To assess the impact of metformin and of two different oral contraceptives (OCs) containing cyproterone acetate and drospirenone, on serum anti-Müllerian hormone (AMH) levels, in a cohort of women with polycystic ovary syndrome (PCOS) with hyperandrogenism. Design.?Prospective randomised study. Setting. Division of Endocrinology and Human Reproduction, Aristotle University of Thessaloniki. Patients.?Forty-five (45) women with PCOS diagnosed according to the criteria proposed in 1990 by the NIH. Interventions.?Women with PCOS were randomised into three groups, all treated for 6 months: Group A received an OC containing 35 μ g ethinylestradiol plus 2 mg cyproterone acetate, Group B received an OC containing 30 μ g ethinylestradiol plus 3 mg drospirenone and Group C received metformin 850 mg × 2. Main outcome measure(s).?Anti-Müllerian hormone levels were measured by a specific ELISA. Results.?AMH was significantly decreased under treatment with 35 μ g ethinylestradiol plus 2 mg cyproterone acetate (p = 0.002 at 3 months and p < 0.001 at 6 months). Treatment with 30 μ g ethinylestradiol plus 3 mg drospirenone, and treatment with metformin 850 mg × 2 did not significantly affect serum AMH levels. AMH was significantly decreased under OCs treatment compared to metformin 850 mg × 2 (p = 0.005). Conclusion(s).?AMH serum levels were significantly decreased under treatment with 35 μ g ethinylestradiol plus 2 mg cyproterone acetate, due to decrease in androgens and suppression of gonadotropins. © 2010 Informa UK, Ltd."
}